CLVS - クロビス・オンコロジ― (Clovis Oncology Inc.)

CLVSのニュース

   Clovis (CLVS) Q1 Earnings and Revenues Surpass Estimates  2020/05/06 15:17:00 Zacks Investment Research
Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues. Shares up.
   Clovis Oncology Announces First Quarter 2020 Operating Results  2020/05/05 20:05:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2020, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for the rest of the year. “We are pleased with our sales growth in the first quarter and believe that Rubraca is well-positioned as an oncology treatment option in the COVID-19 era,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “While we m
   Clovis Oncology to Present at the Bank of America Health Care Conference 2020  2020/04/29 20:05:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America Health Care Conference 2020 on Tuesday, May 12, 2020 at 10:20 a.m. Eastern time. This conference is virtual and a live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of the webcas
   Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?  2020/04/22 13:00:00 Zacks Investment Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
   Clovis Oncology Announces Debt Exchange Transaction  2020/04/14 21:08:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that on April 14, 2020 it entered into a privately negotiated exchange agreement with a holder of its 2.50% Convertible Senior Notes due 2021 (the “2021 Notes”). Pursuant to the exchange agreement, Clovis Oncology will issue to such holder of the 2021 Notes approximately $36.05 million in aggregate principal amount of its currently outstanding series of 4.50% Convertible Senior Notes due 2024 (the “2024 Notes”
   Why Is Clovis (CLVS) Down 41.6% Since Last Earnings Report?  2020/03/25 15:30:23 Zacks Investment Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat  2020/02/25 09:12:00 Zacks Investment Research
Clovis (CLVS) reports mixed fourth-quarter 2019 results. The company's sole marketed drug, Rubraca, drives revenues. Shares down.
   Clovis Oncology (NASDAQ: CLVS): Q4 2019 Earnings Snapshot  2020/02/24 21:13:28 news.alphastreet.com
— Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected. — Product revenues…
   Clovis Oncology Announces 2019 Operating Results  2020/02/24 21:05:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces 2019 Operating Results
   Is Clovis Oncology (CLVS) Outperforming Other Medical Stocks This Year?  2020/02/21 16:30:10 Zacks Investment Research
Is (CLVS) Outperforming Other Medical Stocks This Year?
   Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat  2020/02/25 09:12:00 Zacks Investment Research
Clovis (CLVS) reports mixed fourth-quarter 2019 results. The company's sole marketed drug, Rubraca, drives revenues. Shares down.
   Clovis Oncology (NASDAQ: CLVS): Q4 2019 Earnings Snapshot  2020/02/24 21:13:28 news.alphastreet.com
— Clovis Oncology (NASDAQ: CLVS) reported a fourth-quarter 2019 loss of $1.81 per share versus a loss of $1.71 per share expected. — Product revenues…
   Clovis Oncology Announces 2019 Operating Results  2020/02/24 21:05:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces 2019 Operating Results
   Is Clovis Oncology (CLVS) Outperforming Other Medical Stocks This Year?  2020/02/21 16:30:10 Zacks Investment Research
Is (CLVS) Outperforming Other Medical Stocks This Year?
   Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24  2020/02/13 13:30:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2019 financial results on Monday, February 24, 2020, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovisoncology.com. A replay of the webc

calendar